Medicago Inc. and Mitsubishi Chemical Holdings Corporation Enter into a Collaboration to Develop a Next Generation Technology

Medicago Inc. and Mitsubishi Chemical Holdings Corporation Enter into a 
Collaboration to Develop a Next Generation Technology for Plant Production 
QUEBEC CITY, Jan. 28, 2013 /CNW/ - Medicago Inc. (TSX: MDG) (OTCQX: MDCGF), a 
biopharmaceutical company focused on developing highly effective and 
competitive vaccines based on proprietary manufacturing technologies and 
Virus-Like Particles (VLPs), today announced the execution of a collaboration 
agreement with Mitsubishi Chemical Holdings Corporation ("MCHC") to develop a 
next generation technology for plant production. The objectives of the 
collaboration are to evaluate MCHC's Plant Factory System, a closed 
cultivation system, to produce Nicotiana Benthamiana plants for protein 
production using Medicago's technologies. 
"Our goal is to develop a highly effective, closed plant production system 
with our partner, Mitsubishi," said Andy Sheldon, President and Chief 
Executive Officer of Medicago. "This system would be designed to enhance our 
capacity and further decrease operating costs, whilst facilitating new 
applications of Medicago's technology. We are pleased to build upon our 
existing strategic relationship with Mitsubishi and look forward to continuing 
to strengthen the synergies between our two companies." 
"We are pleased to intensify our collaboration with Medicago to further 
combine our strengths," said Dr. Seiichi Kiso, Executive Officer, Head of 
Healthcare Solutions Office of MCHC "Medicago and Mitsubishi have both 
developed very promising technologies and we see a significant opportunity 
from joining the two technologies into a next generation plant protein 
production platform." 
MCHC has developed a Plant Factory System, a closed hydroponic system to grow 
plants, which is currently used for industrial scale vegetable production in 
Japan and other countries. Using solar panels and LED lighting, it is meant to 
achieve efficient, clean, safe and environmentally friendly plant production 
which is not dependant on weather conditions. These features can provide 
tightly controlled conditions and reproducibility which are key elements to 
ensure reliable biopharmaceutical production in different geographies and 
Under the terms of their collaboration agreement, Medicago and MCHC will work 
together exclusively for one year to evaluate the potential of combining 
MCHC's Plant Factory System with Medicago's plant protein production 
About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel 
vaccines and therapeutic proteins to address a broad range of infectious 
diseases worldwide. The Company is committed to providing highly effective and 
competitive vaccines and therapeutic proteins based on its proprietary VLP and 
manufacturing technologies. Medicago is a worldwide leader in the development 
of VLP vaccines using a transient expression system which produces recombinant 
vaccine antigens in plants. This technology has potential to offer more potent 
vaccines with speed and cost advantages over competitive technologies, 
enabling the development of a vaccine for testing in approximately one month 
after the identification and reception of genetic sequences from a pandemic 
strain. This production time frame has the potential to allow vaccination of 
the population before the first wave of a pandemic, and supply large volumes 
of vaccine antigens to the world market. Medicago also intends to expand 
development into other areas such as biosimilars and biodefense products where 
the benefits of our technologies can make a significant difference. Additional 
information about Medicago is available at 
About Mitsubishi Chemical Holdings Corporation
Mitsubishi Chemical Holdings Corporation (MCHC) is a Japan's leading 
integrated chemical company, and the MCHC Group includes four core operating 
companies: Mitsubishi Chemical Corporation, Mitsubishi Tanabe Pharma 
Corporation, Mitsubishi Plastics, Inc., and Mitsubishi Rayon Co., Ltd. At the 
Group, they serve their customers by using their chemistry-based technology 
platforms to develop a wide range of technologies and products in the fields 
of performance products, healthcare, and industrial materials. Under the Group 
philosophy: "Good Chemistry for Tomorrow", MCHC established a new concept, 
KAITEKI, which encompasses sustainability, health, and comfort. The Group aims 
to realize a truly sustainable state of comfort, not only for individuals but 
also for society and the earth as a whole, by providing their technologies and 
products. Further information about MCHC is available on its website: 
Forward Looking Statements
This news release includes certain forward-looking statements or 
forward-looking information for the purposes of applicable securities laws and 
such statements and information are based upon current expectations, which 
involve risks and uncertainties associated with Medicago's business and the 
environment in which the business operates. Any statements contained herein 
that are not statements of historical facts may be deemed to be 
forward-looking, including those identified by the expressions "anticipate", 
"believe", "plan", "estimate", "expect", "intend", and similar expressions to 
the extent they relate to Medicago or its management. The forward-looking 
statements are not historical facts, but reflect Medicago's current 
expectations regarding future results or events. These forward-looking 
statements are subject to a number of risks and uncertainties that could cause 
actual results or events to differ materially from current expectations, 
including the matters discussed under "Risk Factors and Uncertainties" in 
Medicago's Annual Information Form filed on March 29, 2012, with the 
regulatory authorities. Medicago assumes no obligation to update the 
forward-looking statements, or to update the reasons why actual results could 
differ from those reflected in the forward-looking statements. 
Medicago Inc. Andy Sheldon President and CEO (418) 658-9393 
Medicago Inc. Christina Cameron Investor Relations (418) 658-9393 ext. 156 
SOURCE: Medicago Inc. 
To view this news release in HTML formatting, please use the following URL: 
CO: Medicago Inc.
ST: Quebec
-0- Jan/28/2013 12:00 GMT
Press spacebar to pause and continue. Press esc to stop.